Related Experiment Video
Updated: Mar 4, 2026

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
Published on: April 11, 2025
The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma
Rui Sun1, Henan Qin1, Wenhe Zhang1
1The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Abstract:
Metabolic reprogramming, particularly the dysregulation of cholesterol metabolism, is a hallmark of pancreatic ductal adenocarcinoma (PDAC). However, the underlying molecular drivers remain largely elusive. In this study, we demonstrate that Tribbles homolog 1 (TRIB1) is elevated in PDAC tissues and is significantly associated with poor prognosis. Functionally, TRIB1 mRNA knockdown suppresses PDAC cell growth and tumor formation, while its overexpression promotes both. Mechanistically, TRIB1 protein binds to the DNA-binding domain of PPARγ and inhibits its transcriptional activity. This interaction relieves the PPARγ-mediated repression of HMGCR, the rate-limiting enzyme in the mevalonate pathway, thereby fueling de novo cholesterol biosynthesis. Furthermore, in vivo experiments indicate that PDAC tumors with high TRIB1 expression were more sensitive to the HMGCR inhibitor atorvastatin. Collectively, our findings highlight the critical role of the TRIB1-PPARγ-HMGCR axis in the metabolic rewiring of PDAC and suggest that TRIB1 may serve as a predictive biomarker for optimizing statin-based metabolic therapies.
Insights
Tribbles homolog 1 (TRIB1) drives pancreatic cancer by disrupting cholesterol metabolism via the PPARγ-HMGCR pathway. Targeting this axis with statins may improve treatment outcomes for pancreatic ductal adenocarcinoma (PDAC) patients.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Pathways
Background:
- Pancreatic ductal adenocarcinoma (PDAC) exhibits metabolic reprogramming, including altered cholesterol metabolism.
- The specific molecular mechanisms driving these metabolic changes in PDAC are not fully understood.
Purpose of the Study:
- To investigate the role of Tribbles homolog 1 (TRIB1) in PDAC.
- To elucidate the molecular mechanisms by which TRIB1 influences PDAC progression and cholesterol biosynthesis.
- To evaluate TRIB1 as a potential biomarker for statin therapy.
Main Methods:
- Analysis of TRIB1 expression in PDAC tissues.
- Functional studies involving TRIB1 knockdown and overexpression in PDAC cells.
- Investigation of the interaction between TRIB1 and PPARγ.
- Assessment of HMGCR activity and cholesterol biosynthesis.
- In vivo studies evaluating tumor response to atorvastatin.
Main Results:
- TRIB1 is upregulated in PDAC and correlates with poor prognosis.
- TRIB1 knockdown inhibits PDAC cell growth and tumor formation; overexpression promotes them.
- TRIB1 physically interacts with PPARγ, inhibiting its transcriptional activity.
- This inhibition leads to derepression of HMGCR, enhancing cholesterol biosynthesis.
- PDAC tumors with high TRIB1 expression show increased sensitivity to atorvastatin.
Conclusions:
- The TRIB1-PPARγ-HMGCR axis is crucial for metabolic adaptation in PDAC.
- TRIB1 promotes PDAC progression by fueling cholesterol biosynthesis.
- TRIB1 may serve as a predictive biomarker for statin-based therapies in PDAC.
Related Concept Videos
Cell Specific Gene Expression
Cholesterol: Significance and Regulation
Considering cholesterol and...
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
Chronic Pancreatitis II: Collaborative Care
Assessment:

